Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 15 min ago
Peer-reviewedCC BY-NC 4.0BMJ Open

Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol

  • Jin Li1,2,3,4
  • Nianlan Zhou5
  • Saiquan Lu1
  • Xi Yang1,2,3,4
  • Wangjun Yan2,6
  • Zhengfei Zhu1,2,3,4
  • Mo Cheng2,7
7 affiliations
  1. 1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
  2. 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
  3. 3Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China
  4. 4Shanghai Key Laboratory of Radiation Oncology, Shanghai, China
  5. 5Department of Gastroenterology, Northern Jiangsu People’s Hospital, Yangzhou, China
  6. 6Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
  7. 7Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Open at sourcePDFDOICite

Related

  1. Anti-tumor immunotherapy, radiotherapy, and chemotherapy multimodal combination strategies and interactions in unresectable, locally advanced lung cancer: Clinical practice, mechanism, and biomarker research
    Yan Xu, Hui Guan, Yuan Wu +4
    Journal of translational internal medicinePeer-reviewedCC BYFull textOncologyEurope PMCEurope PMCPMC
  2. Multidisciplinary approach with stereotactic reirradiation to oligoprogressive spinal metastases from dedifferentiated osteosarcoma: a case report
    Arkadiusz Moskwa, Paulina Chmiel, Katarzyna Kozak +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefDOAJ
  3. Qualitative Dynamic Contrast-Enhanced MRI Time–Intensity Curve Analysis for Differentiating Non-Progressive Treatment-Related Changes from Tumor Progression After Stereotactic Radiotherapy for Brain Metastases
    Andrea Romano, Giulia Moltoni, Anna Maria Ascolese +8
    CancersPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  4. Retrospective intrafraction motion verification using triggered kilovoltage images during bone metastases stereotactic body radiotherapy
    Quentin Techer, Noé Grandgirard, Saturnin Sandjong +2
    Physics and Imaging in Radiation OncologyPeer-reviewedCC BY 4.0Full textSystems & synthetic biologyMedical imaging & radiologyHAL
  5. Timing of systemic therapy relative to stereotactic radiosurgery for brain metastases: a real-world cohort study
    Mijal Ptascinsky, Antoni Skripai, Yair Hillman +3
    Journal of Neuro-OncologyPeer-reviewedCC BY 4.0Full textOncologyPMC

Cite

BibTeXRIS
BibTeX
@article{li2026efficacy,
  title = {{Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol}},
  author = {Jin Li and Nianlan Zhou and Saiquan Lu and Xi Yang and Wangjun Yan and Zhengfei Zhu and Mo Cheng},
  journal = {BMJ Open},
  year = {2026},
  month = oct,
  doi = {10.1136/bmjopen-2026-120892},
  url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-120892},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
AU  - Jin Li
AU  - Nianlan Zhou
AU  - Saiquan Lu
AU  - Xi Yang
AU  - Wangjun Yan
AU  - Zhengfei Zhu
AU  - Mo Cheng
PY  - 2026
DA  - 2026/10/01
JO  - BMJ Open
DO  - 10.1136/bmjopen-2026-120892
UR  - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-120892
SN  - 2044-6055
SN  - 2044-6055
ER  -